Literature DB >> 15500591

Adherence to pharmacotherapy in patients with alcohol and opioid dependence.

Roger D Weiss1.   

Abstract

AIMS: An important factor that has thus far limited the effectiveness of pharmacotherapies for patients with alcohol and opioid dependence is poor adherence to medication regimens. This paper presents a review of issues related to medication adherence in patients with these substance use disorders. DESIGN AND METHODS: A literature review was conducted of English language publications relating to medication adherence among patients with alcohol or opioid dependence.
FINDINGS: The paper places the topic in the context of adherence difficulties among patients with a variety of chronic medical and psychiatric illnesses. Difficulties measuring adherence are discussed, and strategies to improve medication adherence are reviewed. These include specific interventions that prescribing clinicians can implement in their individual meetings with patients; the use of external reinforcers, such as positive and negative contingencies, and involvement of family members or significant others; and specific prescribing and dosing practices that may improve adherence.
CONCLUSIONS: As the use of pharmacotherapy for substance-dependent patients increases, rigorous and innovative approaches to encourage medication adherence should be sought.

Entities:  

Mesh:

Year:  2004        PMID: 15500591     DOI: 10.1111/j.1360-0443.2004.00884.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  43 in total

Review 1.  Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 2.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.

Authors:  Katherine J Karriker-Jaffe; Jianguang Ji; Jan Sundquist; Kenneth S Kendler; Kristina Sundquist
Journal:  Addiction       Date:  2017-05-16       Impact factor: 6.526

4.  Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

Authors:  Daniel M Hartung; Dennis McCarty; Rongwei Fu; Katharina Wiest; Mady Chalk; David R Gastfriend
Journal:  J Subst Abuse Treat       Date:  2014-04-13

5.  Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Authors:  Daniel E Falk; Megan L Ryan; Joanne B Fertig; Eric G Devine; Ricardo Cruz; E Sherwood Brown; Heather Burns; Ihsan M Salloum; D Jeffrey Newport; John Mendelson; Gantt Galloway; Kyle Kampman; Catherine Brooks; Alan I Green; Mary F Brunette; Richard N Rosenthal; Kelly E Dunn; Eric C Strain; Lara Ray; Steven Shoptaw; Nassima Ait-Daoud Tiouririne; Erik W Gunderson; Janet Ransom; Charles Scott; Lorenzo Leggio; Steven Caras; Barbara J Mason; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2018-12-09       Impact factor: 3.455

6.  Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.

Authors:  Krysten W Bold; Lisa M Fucito; William R Corbin; Kelly S DeMartini; Robert F Leeman; Henry R Kranzler; Stephanie S O'Malley
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

7.  Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.

Authors:  Kenneth M Carpenter; Huiping Jiang; Maria A Sullivan; Adam Bisaga; Sandra D Comer; Wilfrid Noel Raby; Adam C Brooks; Edward V Nunes
Journal:  Psychol Addict Behav       Date:  2009-03

8.  Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans.

Authors:  Sudie E Back; Julianne C Flanagan; Jennifer L Jones; Isabel Augur; Alan L Peterson; Stacey Young-McCaughan; David W Shirley; Aisling Henschel; Jane E Joseph; Brett T Litz; Allison K Hancock; John D Roache; Jim Mintz; Jennifer S Wachen; Terence M Keane; Kathleen T Brady
Journal:  Contemp Clin Trials       Date:  2018-08-24       Impact factor: 2.226

9.  What happens when people discontinue taking medications? Lessons from COMBINE.

Authors:  Robert L Stout; Jordan M Braciszewski; Meenakshi Sabina Subbaraman; Henry R Kranzler; Stephanie S O'Malley; Daniel Falk
Journal:  Addiction       Date:  2014-09-12       Impact factor: 6.526

10.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Authors:  Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.